Coya Therapeutics is a clinical-stage biotechnology enterprise specializing in the discovery and development of innovative immunotherapies designed to enhance regulatory T cell (Treg) function. Its therapeutic pipelines target complex neurodegenerative, autoimmune, and chronic inflammatory conditions—such as amyotrophic lateral sclerosis (ALS) and Alzheimer's disease—by modulating immune suppression and reducing systemic inflammation through proprietary biologic approaches.